You are here

  • Home
  • Archive
  • Volume 81, Issue 4
  • Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

Article metrics

Article menu
Rheumatoid arthritis
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

 

Online download statistics by month:

Online download statistics by month: August 2021 to November 2024

AbstractFullPdf
Aug 202112281220363
Sep 2021938940305
Oct 2021586582120
Nov 202144243090
Dec 202134534469
Jan 202230030655
Feb 202220320442
Mar 2022967978273
Apr 2022588596142
May 2022468483155
Jun 202241741696
Jul 202227025674
Aug 2022553555126
Sep 2022576585139
Oct 2022502501108
Nov 2022676652103
Dec 202231431084
Jan 202337836569
Feb 202335632275
Mar 202330328458
Apr 202325724280
May 202321120150
Jun 202324623742
Jul 202323523148
Aug 202316416037
Sep 202322721740
Oct 202322520552
Nov 202320520365
Dec 202320217335
Jan 20241019430
Feb 202413412938
Mar 202413713165
Apr 202411510742
May 2024777828
Jun 2024918732
Jul 202411710740
Aug 2024898827
Sep 20241009231
Oct 2024717345
Nov 202416615537
Total13580133393410